Entero Healthcare Solutions is a supply-chain consolidator that stitches together India’s fragmented pharmaceutical distribution market - one acquisition at a time. Founded in 2018 by Prabhat Agrawal and Prem Sethi to bring technology and scale to a USD 33 billion industry dominated by roughly 65,000 small distributors, the company has already completed 51 acquisitions and listed on the BSE and NSE in 2024. The recurring approach is a two-way network effect: more pharmacies and hospitals join because Entero carries products from more than 3,300 manufacturers, and more manufacturers sign on because Entero reaches over 100,000 retail pharmacies - roughly one in every ten in India - across 523 districts. # Business segments A single engine - a pan-India healthcare distribution platform - that earns its keep by buying from manufacturers and selling to pharmacies and hospitals, layered with demand-generation services and a growing private-label and MedTech push. ## 1. Pharmaceutical distribution: the middle mile between factory and pharmacy **Entero buys healthcare products from over 3,300 manufacturers and delivers them to more than 100,000 retail pharmacies and 3,600 hospitals, earning a spread on every unit moved - and growing faster than the market it serves.** - **A hub-and-spoke network that reaches 523 districts** - 136 warehouses across roughly 50 cities feed a last-mile delivery operation covering 20-plus states and union territories, with a total warehouse area of nearly 630,000 square feet. The model scales footprint without requiring a warehouse in every town. - **Organic growth outruns the Indian Pharmaceutical Market** - on a like-for-like basis, Entero grew 15.6% in FY26, meaning it expanded at about 1.6 times the market pace. It is actively deepening its presence in Tier 2 and Tier 3 cities to capture underserved demand. - **Acquisitions are the growth flywheel** - a dedicated on-ground team identifies regional distributors, buys them, and then plugs them into Entero’s technology infrastructure, manufacturer relationships, and central procurement, after which acquired companies have historically grown 60-88% over two to three years. The company has completed 34 acquisitions since inception. - **A two-way network effect locks participants in** - pharmacies and hospitals stay because Entero stocks 97,500 SKUs from thousands of manufacturers; manufacturers stay because Entero gives them direct access to a vast retail base and real-time secondary sales data they cannot get from fragmented small distributors. This dynamic is considered very difficult to replicate. - **Consolidation is still in its early innings** - the top three distributors in India hold only 8-10% of the market, compared with 90-95% for the top three in the US and 95-97% for the top five in Germany, and that share is expected to rise to 20-30% by FY28. ## 2. Demand generation: selling on behalf of the manufacturer **Beyond moving boxes, Entero deploys medical representatives to promote brands to doctors and runs marketing campaigns - turning distribution relationships into commercial partnerships that earn additional fees.** - **A strategic collaboration with Roche since 2020** - Entero promotes, markets, and distributes four nephrology drugs for Roche in India, demonstrating that global pharma companies trust it with brand-facing work, not just logistics. - **New partnerships broaden the service** - in FY25, the company added Servier India for an anti-hypertensive portfolio, Biodis Pharmaceuticals for 4DryField surgical kits, and Abbott for specialty segments including transplant, nephrology, cardiovascular disease, and neurology. Each partnership extends the demand-generation engine into new therapy areas. - **Private labels sit inside this service line** - under the “Entero Surgicals” brand, the company sells homecare medical devices, surgical consumables, and rehabilitation products such as nebulizers, blood pressure monitors, gloves, and adult diapers. The private-label portfolio gives Entero its own margin story on top of distribution spreads. ## 3. MedTech distribution: the new adjacency **Entero entered medical-device distribution in FY26 with three acquisitions, targeting a market projected to grow from USD 13 billion to USD 45-50 billion by FY35 - and it expects the segment to cross INR 1,000 crore in revenue in FY27.** - **Synergy with the existing pharma infrastructure** - the same warehouses, delivery fleet, and pharmacy relationships that move pharmaceuticals can also move in-vitro diagnostics (IVD), cardiology devices, and orthopaedic implants, so the expansion leverages assets already in place. - **Higher margins than pharma distribution** - the MedTech supply chain offers a higher value-add role for distributors and a better margin profile, making it an attractive adjacency to the core business. - **Three acquisitions built the entry** - Ace Cardiopathy Solutions (Delhi, cardiology, 60% stake), Bioaide Technologies (Delhi, cardiology/ENT/CNS, 80% stake), and Anand Chemiceutics (Pune, IVD, 51.5% stake) gave Entero immediate footing in the two segments it is targeting: IVD and cardiology/orthopaedic devices. # Technology platform **A proprietary, in-house-built digital backbone gives every participant - pharmacy, hospital, manufacturer, and sales rep - a single interface to order, track, analyse, and promote, making the network stickier and the operation more efficient.** - **One-touch ordering for pharmacies and hospitals** - the platform provides live inventory visibility, consolidated ledgers, scheme visibility, and order-status tracking, so a retail chemist can manage procurement without juggling dozens of distributor relationships. - **Real-time data for manufacturers** - the platform delivers secondary sales data, inventory levels, and micro-market insights, giving manufacturers visibility they lack when dealing with fragmented small distributors. This data feed is a reason manufacturers stay in the network. - **HealthEdge turns chemists into digital storefronts** - launched in FY25, this chemist-club programme lets retail pharmacies create personalised e-stores and websites, offers credit facilities, and integrates with the government’s Digital Health Incentive Scheme, deepening the relationship with the pharmacy counter. # Group structure and partners **Entero Healthcare Solutions is the listed parent atop 47 subsidiaries, with promoter-founders at the helm, a significant healthcare-focused institutional shareholder, and a structure built to absorb acquired distributors while keeping minority partners aligned.** - **Promoter-led with institutional backing** - Prabhat Agrawal (MD & CEO) and Prem Sethi (Whole-time Director & COO) run the business, while OrbiMed Asia III Mauritius Limited holds a significant stake and places two nominee directors on the eight-member board. - **Subsidiaries are the acquisition chassis** - key operating entities include R S M Pharma, Novacare Healthcare Solutions, Chethana Pharma, and Chirag Medicare Solutions, many of which are wholly owned, and the company routinely uses rights issues and optionally convertible debentures to fund subsidiaries. - **Minority stakes align acquired promoters** - non-controlling interests on the balance sheet reflect the stakes retained by founders of acquired companies, with goodwill of INR 749 crore capturing the premium paid for those acquisitions. The structure buys control while keeping local operators invested.